Sun Jinmei, Xing Fengbo, Feng Jingjing, Chen Xin, Lv Lingling, Yao Xiaoqing, Wang Mengqi, Zhao Ziye, Zhou Qian, Liu Tingting, Zhan Yuqian, Gong-Jun J I, Wang Kai, Hu Panpan
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230000, China.
Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei, 230032, China.
Heliyon. 2024 Jun 12;10(12):e32799. doi: 10.1016/j.heliyon.2024.e32799. eCollection 2024 Jun 30.
Repetitive transcranial magnetic stimulation (rTMS) is an effective noninvasive neuromodulation technique for Parkinson's disease (PD). However, the efficacy of rTMS varies widely between individuals. This study aimed to investigate the factors related to the response to rTMS in PD patients.
We retrospectively analyzed the response of 70 idiopathic PD patients who underwent rTMS for 14 consecutive days targeting the supplementary motor area (SMA) in either an open-label trail (n = 31) or a randomized, double-blind, placebo-controlled trial (RCT) (n = 39). The motor symptoms of PD patients were assessed by the United Parkinson's Disease Rating Scale Part III (UPDRSIII). Based on previous studies, the UPDRSIII were divided into six symptom clusters: axial dysfunction, resting tremor, rigidity, bradykinesia affecting right and left extremities, and postural tremor. Subsequently, the efficacy of rTMS to different motor symptom clusters and clinical predictors were analyzed in these two trails.
After 14 days of treatment, only the total UPDRSIII scores and rigidity scores improved in both the open-label trial and the RCT. The results of multiple linear regression analysis indicated that baseline rigidity scores (β = 0.37, p = 0.047) and RMT (β = 0.30, = 0.02) positively predicted the improvement of UPDRSIII. The baseline rigidity score (β = 0.55, < 0.0001) was identified as an independent factor to predict the improvement of rigidity.
This study demonstrated significant improvements in total UPDRSIII scores and rigidity after 14-day treatment, with baseline rigidity scores and RMT identified as predictors of treatment response, underscoring the need for individualized therapy.
重复经颅磁刺激(rTMS)是一种用于帕金森病(PD)的有效的非侵入性神经调节技术。然而,rTMS的疗效在个体之间差异很大。本研究旨在探讨与PD患者rTMS反应相关的因素。
我们回顾性分析了70例特发性PD患者的反应,这些患者在开放标签试验(n = 31)或随机、双盲、安慰剂对照试验(RCT)(n = 39)中连续14天针对辅助运动区(SMA)进行rTMS治疗。通过统一帕金森病评定量表第三部分(UPDRSIII)评估PD患者的运动症状。基于先前的研究,将UPDRSIII分为六个症状簇:轴性功能障碍、静止性震颤、肌强直、影响左右肢体的运动迟缓以及姿势性震颤。随后,在这两项试验中分析了rTMS对不同运动症状簇的疗效及临床预测因素。
治疗14天后,开放标签试验和RCT中仅UPDRSIII总分和肌强直评分有所改善。多元线性回归分析结果表明,基线肌强直评分(β = 0.37,p = 0.047)和静息运动阈值(RMT)(β = 0.30,p = 0.02)正向预测UPDRSIII的改善情况。基线肌强直评分(β = 0.55,p < 0.0001)被确定为预测肌强直改善的独立因素。
本研究表明,治疗14天后UPDRSIII总分和肌强直有显著改善,基线肌强直评分和RMT被确定为治疗反应的预测因素,强调了个体化治疗的必要性。